Exchange: NASDAQ·Updated 07:57 PM EDT

OCGN News

News
all
press releases
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 8, 2026Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would...
PR Newswire
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 8, 2026Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would...
PR Newswire
More News
Transcript: Ocugen Q2 2026 Earnings Conference Call
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.read more...
Benzinga
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.
Stocktwits
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Zacks
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Zacks
Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.
Zacks

Advertisement|Remove ads.